WS #16095
The biotech sector is active with M&A and clinical developments. Merck KGaA is acquiring Silence Therapeutics for $1.3 billion at a 130% premium, adding siRNA technology. In contrast, EyePoint Pharmaceuticals is plunging after a late-stage trial setback for its lead drug. Novavax sees its largest shareholder, Shah Capital, sell $32.6 million in stock and end its activist campaign, signaling a loss of near-term catalyst support. These mixed signals highlight the high risk/reward nature of the sector.
Biotech M&A and Clinical
The biotech sector is active with M&A and clinical developments. Merck KGaA is acquiring Silence Therapeutics for $1.3 billion at a 130% premium, adding siRNA technology. In contrast, EyePoint Pharmaceuticals is plunging after a late-stage trial setback for its lead drug. Novavax sees its largest shareholder, Shah Capital, sell $32.6 million in stock and end its activist campaign, signaling a loss of near-term catalyst support. These mixed signals highlight the high risk/reward nature of the sector.